ReviewAnatolian journal of cardiology2025
From Metabolic Syndrome to Cardiovascular-Kidney-Metabolic Syndrome and Systemic Metabolic Disorder: A Call to Recognize the Progressive Multisystemic Dysfunction.
Review in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sarcopenic Obesity and Cardiovascular Disease Risk and Mortality: A Systematic Review and Meta-Analysis.Anatolian journal of cardiology · 2025Pooled it
- Exercise as a Molecular Therapeutic Strategy in Metabolic Syndrome: Integrating Cellular Signaling, Organ Crosstalk, and Clinical Translation-A Narrative Review.Current issues in molecular biology · 2026Review
- Vitamin D and Metabolic Syndrome: Molecular Mechanisms and Clinical Implications: A Narrative Review.International journal of molecular sciences · 2026Review
- Observational
- Glucocorticoid resistance-induced inflammation drives cardiovascular-kidney-metabolic (CKM) syndrome pathophysiology.Trends in endocrinology and metabolism: TEM · 2026Review
- Review
- Associations between cardiovascular-kidney-metabolic syndrome staging and risks of all-cause and cardiovascular mortality: a systematic review and meta-analysis.American journal of preventive cardiology · 2026Article
- A metabolic-to-inflammatory pattern in cardiovascular-kidney-metabolic syndrome staging: a comparative cross-sectional study.Frontiers in endocrinology · 2026Article
- Malondialdehyde-Superoxide Dismutase Redox Imbalance as an Early Biological Risk Indicator in Young Adult Smokers.Vascular health and risk management · 2026Article
- Anthocyanins Modulation of Gut Microbiota to Reverse Obesity-Driven Inflammation and Insulin Resistance.Nutrients · 2025Review
- Comparison of Risk Stratification Tools for Atherosclerotic Cardiovascular Disease and Cardiovascular-Kidney-Metabolic Syndrome in Primary Care.Medical sciences (Basel, Switzerland) · 2025Observational
- Epigenetic pharmacology in aging: from mechanisms to therapies for age-related disorders.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The landscape of metabolic health has evolved dramatically in recent years. Once viewed as a collection of distinct conditions, disorders like obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, and fatty liver disease are now understood to share common pathophysiological roots. This review explores the transition from the traditional concept of metabolic syndrome toward more comprehensive and clinically relevant frameworks, namely, the cardiovascular-kidney-metabolic (CKM) syndrome proposed by the American Heart Association, and the systemic metabolic disorder (SMD) framework introduced by the European Atherosclerosis Society. Both models recognize the progressive, multisystemic nature of metabolic dysfunction, highlight the need for stage-based risk stratification, and emphasize early intervention. The authors discuss the central role of dysfunctional adiposity and ectopic fat in driving organ-specific damage, and examine the growing body of evidence supporting the use of novel therapies such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), and gastric inhibitory polypeptide (GIP)/GLP-1RA in delivering multiorgan protection. By comparing the CKM and SMD models, the authors highlight their complementary nature and shared call for a shift in clinical thinking away from isolated management and toward integrated, multidisciplinary care. As the burden of metabolic dysfunction continues to rise, the need to recognize obesity as a chronic disease and to develop practical, collaborative strategies across cardiology, nephrology, endocrinology, and hepatology becomes even more urgent. The rise of cardiometabolic medicine offers a timely and necessary response to this growing challenge, creating opportunities for better prevention, earlier detection, and improved outcomes for the patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.